Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Renal Impairment

Key Inclusion Criteria: * Cohorts 1 and 3: Participants with Severe or Moderate Renal Impairment * Body mass index (BMI) of greater than or equal to (\>=)18.0 to less than (\<) 40.0 kilogram per square meter (kg/m\^2) * Stable renal function as pre-defined in the protocol * Cohorts 2 and 4: Matched Healthy Participants * Healthy participants will be matched to Cohorts 1 and 3 participants according to each of the following parameters: sex, age (±10 years), and BMI (±15%) Key Exclusion Criteria: * Cohorts 1 and 3: Participants with Severe or Moderate Renal Impairment * Hemoglobin less than or equal to (≤) 9.0 gram per deciliter (g/dL) at screening * Cohorts 2 and 4: Matched Healthy Participants * Prior renal transplantation, prior hemodialysis, or prior peritoneal dialysis * All Cohorts: * History of febrile or acute illness that has not fully resolved by 14 days before study drug dosing. * Any condition possibly affecting drug absorption Other protocol defined Inclusion/Exclusion criteria may apply.